Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 680-681, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cole, T. G.
Right arrow Articles by Krause, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cole, T. G.
Right arrow Articles by Krause, B. R.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2002;48:680-681.)
© 2002 American Association for Clinical Chemistry, Inc.

Letters

Method-dependent Changes in "HDL-Cholesterol" with Recombinant Apolipoprotein A-IMilano Infusion in Healthy Volunteers

Thomas G. Cole1a, William L. Nowatzke1, Charles L. Bisgaier2 and Brian R. Krause2

1 Core Laboratory for Clinical Studies, Washington University, School of Medicine, St. Louis, MO 63110

2 Esperion Therapeutics, Inc., Ann Arbor, MI 48108

aAuthor for correspondence. Fax 314-362-4782; e-mail thom@im.wustl.edu.


To the Editor:

Warnick et al. (1) recently reviewed the status of the measurement of HDL-cholesterol (HDL-C) and cautioned against the use of the new homogeneous methods, when atypical specimens may be present, without additional validation of the accuracy of the methods. We recently had the opportunity to analyze specimens from a clinical trial, which will serve as an excellent example of the warning given by these authors.

In a phase I clinical trial, 32 healthy volunteers were infused with a synthetic HDL comprising recombinant apolipoprotein (Apo) A-IMilano and phospholipid [1-palmitoyl-2-oleoyl-sn-3-glycerophosphocholine (POPC)]. This cholesterol-free, HDL-like complex is referred to as ETC-216. The intent of the trial was to determine safety/tolerability before initiating a phase II study in patients with acute coronary syndromes. It has been suggested that ApoA-IMilano/phospholipid infusions may rapidly stabilize atherosclerotic lesions by mobilizing vessel wall cholesterol (2).

Initial measurements of HDL-C concentrations before and 30 min after the start of the infusion gave divergent results when we compared results obtained . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.